Embedded Files
GLYCOPEPTIDE SUSCEPTIBILITY AMONG STAPHYLOCOCCI AND ENTEROCOCCI ISOLATES FROM SULAIMANI HEALTH LABORATORIES
GLYCOPEPTIDE SUSCEPTIBILITY AMONG STAPHYLOCOCCI AND ENTEROCOCCI ISOLATES FROM SULAIMANI HEALTH LABORATORIES
Razaw Mofaq Rashid a and Sherko A. Omer b
Razaw Mofaq Rashid a and Sherko A. Omer b
a Kurdistan Board Medical Studies Candidate, Public Health Laboratory, Sulaimani Directorate of Health.
b Department of Microbiology, College of Medicine, University of Sulaimani.
Submitted: 25/4/2018; Accepted: 14/10/2018; Published 21/12/2018
DOI Link: https://doi.org/10.17656/jsmc.10176
ABSTRACT
Background
Glycopeptide antibiotics are bactericidal agents that inhibit late stage bacterial cell wall peptidoglycan synthesis in Gram-positive bacteria. They are used for multiresistant Gram-positive cocci infection such as staphylococci and enterococci.
Objectives
To determine glycopeptide susceptibility among staphylococci and enterococci isolates from Sulaimani city health laboratories and find combined methicillin and vancomycin resistance among S. aureus isolates.
Materials and Methods
Isolates of staphylococci and enterococci were collected from different hospital laboratories and community health laboratories in Sulaimani city. Staphylococci were differentiated based on coagulase test while enterococci species were determined using Vitek 2 ®automated system. Antimicrobial susceptibility test was preformed according to the Bauer-Kirby disk diffusion method using vancomycin, teicoplanin, amoxicillin-clavulanate, cefoxitin, methicillin, erythromycin, amikacin, gentamicin and netilmicin disks. The susceptibility was determined according to the Performance Standards for Antimicrobial Disk Susceptibility Tests.
Results
A total of 207 isolates of staphylococci and enterococci were collected from six hospital laboratories and two community health laboratories in Sulaimani city. The isolates were 146 Staphylococcus aureus, 36 coagulase-negative staphylococci (CoNS) and 25 enterococci isolates. The isolates were from inpatients 182 (87.9%), the other 25 (12.1%) were from outpatients submitting their specimens to community health laboratories. Resistance to vancomycin was detected in one isolate of each S. aureus (0.7%), CoNS (2.8%) andenterococci species (4%). For teicoplanin, one S. aureus isolate showed intermediate response (0.7) and two isolates (1.4%) were resistant. One isolate of each CoNS (2.8%) and enterococci spp. (4%) was resistant to teicoplanin. One MRSA isolate (1.25%) was resistant to vancomycin and combined resistance to both vancomycin and teicoplanin was detected in three isolates.
Conclusion
Glycopeptide resistance was reported in staphylococci and enterococci but was uncommon. The reported resistance advises regular observation and monitoring the antibiotic susceptibility and strict antibiotic policy. Glycopeptide alternative still can be used in treatment of some Gram-positive infections, this may delay the emergence and spread of glycopeptide resistance.
KEYWORDS
Glycopeptide susceptibility, S. aureus, CoNS, enterococci, Sulaimani.
References
1. Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. European Journal of Clinical Microbiology & Infectious Diseases. 1989;8(11):943-50.
2. Dancer SJ. Glycopeptide resistance in Staphylococcus aureus. Journal of Antimicrobial Chemotherapy. 2003;51(5):1309-11.
3. Pottinger P, Reller LB, Ryan KJ. Antibacterial Agents and Resistance. In: Ryan KJ, Ray CG, editors. Sherris Medical Microbiology. Sixth ed. New York: Mcgraw-hill; 2014.
4. Murray BE, Arias CA, C. NE. Glycopeptides (Vancomycin and Teicoplanin), Streptogramins (Quinupristin-Dalfopristin), Lipopeptides (Daptomycin), and Lipoglycopeptides (Telavancin). In: Bennett JE, Dolin R, Blaster MJ, editors. Mandell, Douglas, and Bennett’s Principles and Practice of INFECTIOUS DISEASES. 1. Eighth Edition ed. Philadelphia, PA: Saunders, Elsevier; 2015. p. 437-00.
5. Ahlstrand E, Svensson K, Persson L, Tidefelt U, Söderquist B. Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades. European journal of clinical microbiology & infectious diseases. 2011;30(11):1349-54.
6. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. New England Journal of Medicine. 1987;316(15):927-31.
7. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet (London, England). 1998;351(9110):1212.
8. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. The Journal of antimicrobial chemotherapy. 1997;40(1):135-6.
9. Report MaMW. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. MMWR Morb Mortal Wkly Rep. 1997;46(33):765-6.
10. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clinical microbiology reviews. 2000;13(4):686-707.
11. Sujatha S, Praharaj I. Glycopeptide Resistance in Gram-Positive Cocci: A Review. Interdisciplinary Perspectives on Infectious Diseases. 2012;2012:10.
12. Cosgrove S, Carroll K, Perl T. Staphylococcus aureus with reduced susceptibility to vancomycin. Clinical infectious diseases. 2004;39(4):539-45.
13. Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annual Reviews in Microbiology. 2002;56(1):657-75.
14. Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in staphylococci. Clinical microbiology reviews. 2002;15(3):430-8.
15. Rogers KL, Fey PD, Rupp ME. Coagulase-negative staphylococcal infections. Infectious disease clinics of North America. 2009;23(1):73-98.
16. Fainstein V, LeBlanc B, Bodey GP. Comparative in vitro study of teichomycin A2. Antimicrobial agents and chemotherapy. 1983;23(3):497-9.
17. Wilson A, O'hare M, Felmingham D, Grüneberg R. Teicoplanin-resistant coagulase-negative staphylococcus. The Lancet. 1986;328(8513):973.
18. Bene VED, John JF, Twitty JA, Lewis JW. Anti-staphylococcal activity of teicoplanin, vancomycin, and other antimicrobial agents: the significance of methicillin resistance. The Journal of infectious diseases. 1986;154(2):349-52.
19. Veach L, Pfaller M, Barrett M, Koontz F, Wenzel R. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. Journal of clinical microbiology. 1990;28(9):2064-8.
20. Sanyal D, Johnson A, George R, Cookson B, Williams A. Peritonitis due to vancomycin-resistant Staphylococcus epidermidis. The Lancet. 1991;337(8732):54.
21. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2006;12 Suppl 1:16-23.
22. Tiwari HK, Sen MR. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infectious diseases. 2006;6(1):156.
23. Showsh SA, De Boever EH, Clewell DB. Vancomycin resistance plasmid in Enterococcus faecalis that encodes sensitivity to a sex pheromone also produced by Staphylococcus aureus. Antimicrobial agents and chemotherapy. 2001;45(7):2177-8.
24. Billot-Klein D, Gutmann L, Bryant D, Bell D, Van Heijenoort J, Grewal J, et al. Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics. Journal of bacteriology. 1996;178(15):4696-703.
25. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. New England Journal of Medicine. 1988;319(3):157-61.
26. Méndez-Álvarez S, Pérez-Hernández X, Claverie-Martín F. Glycopeptide resistance in enterococci. International Microbiology. 2000;3(2):71-80.
27. Foster T. Staphylococcus. In: Baron S, editor. Medical Microbiology Fourth ed. Texas: University of Texas Medical Branch at Galveston, Galveston, Texas; 1996.
28. Bauer A, Kirby W, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. American journal of clinical pathology. 1966;45(4):493.
29. Performance Standards for Antimicrobial Susceptibility Testing M100; Twenty-Fifth Informational Supplement. Wayne, PA: CLSI; 2015
30. Performance Standards for Antimicrobial Susceptibility Testing M100; Seventeenth Informational Supplement. Wayne, PA: CLSI;2007.
31. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infection Control & Hospital Epidemiology. 2013;34(1):1-14.
32. Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, et al. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007–11 study. Journal of Antimicrobial Chemotherapy. 2013;68(suppl_1):i7-i22.
33. O’Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infection and drug resistance. 2015;8:217.
34. Bhamare B, Karmarkar A, Iyer V, Bhardwaj R, Deshpande S, Kagal A. Study of prevalence of methicillin and vancomycin resistance in multidrug resistant coagulase negative staphylococci. International J of Healthcare and Biomedical Research. 2014;2(3):67-72.
35. Aligholi M, Emaneini M, Jabalameli F, Shahsavan S, Dabiri H, Sedaght H. Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran. Medical Principles and Practice. 2008;17(5):432-4.
36. Al-Dahbi AM, Al-Mathkhury HJ. Distribution of Methicillin Resistant Staphylococcus aureus in Iraqi patients and Healthcare Workers. Iraqi J Sci. 2013;54(2):293-300.
37. Walters MS, Eggers P, Albrecht V, Travis T, Lonsway D, Hovan G, et al. Vancomycin-Resistant Staphylococcus aureus - Delaware, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(37):1056.
38. Jalal SM, Omer SA, Anwer KA. Bacteriological and PCR Detection of pvl, msrA and mecA Genes among Staphylococcus aureus isolated from Burn Wounds. Sulaimani, Iraq: University of Sulaimani, College of Medicine; 2017.
39. Davoudi A, Najafi N, Alian S, Tayebi A, Ahangarkani F, Rouhi S, et al. Resistance pattern of antibiotics in patient underwent open heart surgery with nosocomial infection in North of Iran. Global journal of health science. 2016;8(2):288.
40. Tiemersma EW, Bronzwaer SL, Lyytikäinen O, Degener JE, Schrijnemakers P, Bruinsma N, et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerging infectious diseases. 2004;10(9):1627.
41. Pichler G, Pux C, Babeluk R, Hermann B, Stoiser E, De Campo A, et al. MRSA prevalence rates detected in a tertiary care hospital in Austria and successful treatment of MRSA positive patients applying a decontamination regime with octenidine. European Journal of Clinical Microbiology & Infectious Diseases. 2018;37(1):21-7.
42. Flournoy D, Robinson M. In vitro antimicrobial susceptibilities of 349 methicillin-resistant Staphylococcus aureus isolates from veterans. Methods and findings in experimental and clinical pharmacology. 1990;12(8):541-4.
© The Authors, published by University of Sulaimani, College of Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Page updated
Report abuse